---
source_image: "chart+spreadsheet__EFTA01457577_20260130_p001_i001.png"
source_pdf: "EFTA01457577.pdf" 
method: pdf_text
words: 579
confidence: 1.00
extracted: 2026-02-15T18:38:11.880555
---

-CO 
-BO 
-100 
-1/0 
•140 
27 May 2015 
Biotechnology 
Retrophin 
Model updated:27 May 2015 
It n:nay) the not:lb.:ff. 
North America 
United States 
Biotechnology 
Retrophin 
Reuters: RTRX.OQ 
Buy 
Price I26 May 151 
Target Pricy 
52 Week range 
Market Cap (ml 
Bloomberg: RTRX US 
USD 76.87 
USD 52.00 
USD 8.09 - 26.98 
USDm 949 
EURrn 871 
Cori inAny Pi °filo 
Riarophin is • temdurm•cetnical company focused on 
discovering. 
developing 
and 
marketing 
iroovative 
therapies for debilitating end often lite -threatening 
diseases 
!Pt gin Perforranncu 
28 
24 
10 
16 
12 
4 
0 
Dec '2 
Jun" 3 
Cvc "3 
Jun '4 
Oec 
—
144014.11 
 
 414400 41010114•4n40 
MarGin 
83
82 
90 
89 
87 
86 
84  
'4 
ISE 
(tE 
17E 
-4.- a444 1111DAM/44. 
Dz OMR St Ptrifilabitity 
200 
150 
100 
50 
EST Morn 
Senrowin(U441. 
SBA 
50 
40 
30 
20 
10 
0 
117 
14 
15E 
10E 
17E 
gmg -....worr wow row Ow,/ 
Roffrn Ktinausl- as 
.1 212 250-7591 
rObyokerrnougreSSOS corn 
Page 
Fiscal yam end 31-Disc 
IFinnnevil Sunti mere 
08 EPS IUSCI 
Awned EPS (USD) 
OPS (USDI 
8VPS 27501 
2014 
2015E 
2016E 
2017E 
-251 
084 
0.00 
-1.49 
1 65 
063 
000 
607 
100 
108 
213 
219 
000 
000 
788 
989 
Vet, tenon Monet.. 
Price/Saba Ixl 
P/E (08) I.1 
pit (Remitted) (4 
PAW lx) 
FCF yield 
Dividend yield 1961 
EV/Salm 
EV/E8ITDA 
EWE8IT 
11.2 
11 6 
8.0 
5.9 
nm 
163 
209 
248 
15.0 
428 
12.0 
12.3 
nm 
44 
34 
27 
293 
49 
13.7 
13.2 
0.0 
00 
00 
0.0 
10.2 
110 
110 
83 
94 
94 
50 
5.8 
58 
33 
3 
38 
Income fitainn rit itfiDnit 
Saks 
EBITDA 
EMT 
Pre-tax groin 
Nat income 
28 
81 
119 
160 
28 
72 
103 
136 
28 
72 
103 
136 
29 
72 
103 
136 
31 
30 
103 
108 
(>3111 low IIJ`ilinti
Cash flow from operations 
Net Codex 
Free cash flow 
Equity raned/f bought backl 
Dividends paid 
Net incAdeci in konomogs 
Other imastingrfetencing can flows 
Net cash flow 
Chong* In working wits; 
(ielance Sl,a l (USOir) 
Cohen] caM squwww 
PRIMO/. Print a equipment 
Goodwill 
Other sets 
Total assets 
Debt 
Other bedlam' 
Total hatillties 
Total share/443N ' 444.4ty 
Abt debt 
agiildoblE4.3 
50 
139 
137 
-4 
.4 
4 
ee 
135 
133 
150 
0 
0 
0 
0 
0 
O 
0 
0 
O 
0 
0 
186 
135 
133 
-4 
70 
2 
Kitt- Company Metrics 
Sole growth egri 
DB EPS growth 66) 
Payout ratio 1361 
EBITDA Margin 1161 
EMT Margin 60 
ROE (36) 
Net debt/400y MAI 
Net intemat cover (x) 
Ditr31411 AnniV141 
EBrt r"4610 1361 
x Anat turnover ftit 
x Financial toe' ratio Cd 
x Tax end other eff acts 1.1 
. ROA (poet tax) Pffil 
X Financial levere4s1x) 
. ROE Off 
rinnuargrowel 
x NTA/shans (await.) 
Reported EPS 
annual growth MN 
Sauce Company dim Deutsche Bank esonusiss 
18 
262 
342 
420 
1 
5 
8 
11 
O 
0 
0 
0 
117 
109 
109 
109 
135 
376 
459 
541 
O 
0 
0 
0 
173 
161 
171 
173 
173 
161 
171 
173 
-37 
214 
288 
368 
48 
-262 
442 
-420 
nm 
1990 
463 
338 
na 
na 
-39.4 
8.2 
0.0 
0.0 
0.0 
0.0 
928 
IVO 
807 
855 
922 
880 
86.7 
85.5 
nm 
338 
41.2 
32.9 
nm 
-122 2 
-118.8 
-114.3 
nm 
nm 
rint 
ram 
922 
880 
88.7 
85.5 
02 
03 
03 
03 
1.0 
10 
1.0 
1.0 
1.2 
04 
1.0 
08 
229 
11.7 
24,8 
21.6 
-36 
29 
17 
I 5 
433.2 
338 
41.2 
32.9 
no 
mo 
27.9 
-20 7 
-1.0 
19 
5.2 
6.7 
0.84 
063 
213 
219 
no 
-246 
2321 
2.7 
Deutsche Bank Securities Inc. 
CONFIDENTIAL 
— PURSUANT TO FED. R. CRIM. P. 6(e) 
DB-SDNY-0117182 
CONFIDENTIAL 
SDNY_GM_00263366 
EFTA01457577